Latest news

• Incyte’s JAK inhibitor cream clears second eczema trial

  Its closest rival is likely to be Pfizer’s PDE-4 inhibitor  Eucrisa (crisaborole) ointment, which was approved in the US in 2016, and generic corticosteroid creams that cause side effects ... Eucrisa’s sales were just $138m last year, down 7%. Other

• MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

  dupilumab) for moderate-to-severe symptoms and Pfizer’s  Eucrisa (crisaborole) for milder forms.

• Daily brief: Novartis spends big on ezcema, Kite invests, another gene therapy IPO

  There is plenty of competition in the field, with Pfizer’s Eucrisa and Regeneron and Sanofi’s Dupixent already on the market.

• Dermira craters as acne drug fails late-stage test

  s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is

• Roche out-licenses lebrikizumab rights to Dermira

  Meanwhile, Pfizer is starting to make headway with its new topical treatment Eucrisa (crisaborole), which pulled in $17m in the first half of the year after its approval last December.